Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

VanEck Pharmaceutical ETF (NQ:PPH)

101.67 +0.23 (+0.23%)
Streaming Delayed Price Updated: 9:39 AM EST, Dec 19, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about VanEck Pharmaceutical ETF

< Previous 1 2 Next >
News headline image
3 Weight-Loss ETFs to Profit From the Obesity Drug Boom ↗
Leverage Oprah's shift to prescription weight solutions with Weight-Loss ETFs, targeting companies leading in obesity treatment. 
Via InvestorPlace
Topics ETFs
News headline image
Novo Nordisk's Game-Changer: FDA Approves Weight Loss Sensation Wegovy For Heart Health, Potential Insurance Coverage ↗
Novo Nordisk's Wegovy receives FDA approval for expanded use, targeting a significant reduction in cardiovascular events and weight management. 
Via Benzinga
News headline image
The Top 3 ETFs to Buy in March 2024 ↗
Simplify your investment strategy through these top ETFs to buy, offering an excellent blend of diversification and upside. 
Via InvestorPlace
Topics ETFs
News headline image
11 'Granolas' Stocks Outperform Magnificent 7 With Lower Volatility, Higher Yields ↗
A group of stocks, which Goldman Sachs dubbed the "Granolas," accounted for 50% of gains of the Stoxx Europe 600 Index for the past year. 
Via Benzinga
News headline image
A Look At Pharma ETFs After Q4 Earnings ↗
The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. 
Via Talk Markets
Topics ETFs
News headline image
5 ETF Zones Scaling New Highs At The Start Of 2024 ↗
The start of 2024 has been weak for the global stock market after a blockbuster 2023. Still, a few corners of the stock market are outperforming, pushing ETFs to new 52-week highs. 
Via Talk Markets
Topics ETFs
News headline image
Government-granted Patent Monopolies Are Not The Free Market ↗
Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... 
Via Talk Markets
Topics Intellectual Property
News headline image
Preparing For The Next Short-Term Rally Higher ↗
The short-term downtrend appears set to continue. The market is taking the time it needs to consolidate near its short-term trend lows in order to prepare a base from which it can begin its next... 
Via Talk Markets
News headline image
Pharma ETFs in Focus Post Q2 Earnings ↗
Second-quarter earnings for the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 30.7% on 5% revenue growth. 
Via Talk Markets
Topics ETFs
News headline image
The 3 Most Undervalued Pharma Stocks to Buy Now: July 2023 ↗
Trading below a 15 forward price-to-earnings, these undervalued pharma stocks offer opportunities in an overbought market. 
Via InvestorPlace
News headline image
Pharma ETFs Gain Post Q1 Earnings ↗
Pharma ETFs have been in the green over the past month. 
Via Talk Markets
News headline image
A Look At Pharma ETFs Post Q4 Earnings ↗
Many industry bigwigs reported solid results, with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
News headline image
5 Sector ETFs That Beat The Market In December ↗
While most segments of the market are suffering from huge losses, a few have performed really well. These are likely to continue outperforming should the trends prevail. 
Via Talk Markets
News headline image
Pharma ETFs In Focus Post Q3 Earnings ↗
Many industry bigwigs reported solid results with some beating on earnings or revenues or both. However, solid earnings failed to fully impress pharma ETFs over the past month. 
Via Talk Markets
News headline image
Wave of Solid Q3 Earnings Push Pharma ETFs Higher ↗
The slew of Q3 results has led to smooth trading in pharma ETFs over the past month. 
Via Talk Markets
News headline image
Pharma ETFs in Focus Post Q1 Earnings ↗
The slew of Q1 results has led to mixed trading in pharma ETFs over the past month. Here are those in detail. 
Via Talk Markets
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.